SCHEMBL8024787

SCHEMBL8024787

[CH2]CC(=O)c1ccc([N+](=O)[O-])cc1

nearest known ligand 0.67

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.67
CES1 P23141 2/20 0.61
CA1 P00915 2/20 0.59
CA2 P00918 2/20 0.59
TDP1 Q9NUW8 1/20 0.59
TSHR P16473 1/20 0.57
ALDH1A1 P00352 1/20 0.57
MAPK1 P28482 1/20 0.57
CES2 O00748 1/20 0.53
SRD5A2 P31213 1/20 0.53
HSD11B1 P28845 1/20 0.53
LMNA P02545 1/20 0.52
GAA P10253 1/20 0.52
MMP8 P22894 1/20 0.51
PKM P14618 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27447197 0.85 GSK3B (0.62) GSK3BCES1CA1CA2TDP1
SCHEMBL11510574 0.83 GSK3B (0.71) GSK3BCES1CA1CA2TDP1
SCHEMBL240086 0.83 GSK3B (0.71) GSK3BCES1CA1CA2TDP1
SCHEMBL220960 0.82 GSK3B (0.69) GSK3BCES1CA1CA2TDP1
SCHEMBL11713734 0.82 GSK3B (0.69) GSK3BCES1CA1CA2TDP1
SCHEMBL2867066 0.80 GSK3B (0.67) GSK3BCES1CA1CA2TDP1
SCHEMBL6155163 0.80 GSK3B (0.67) GSK3BCES1CA1CA2TDP1
SCHEMBL73490 0.80 GSK3B (1.00) GSK3BCES1CA1CA2TDP1
SCHEMBL671514 0.80 GSK3B (0.67) GSK3BCES1CA1CA2TDP1
SCHEMBL255510 0.80 GSK3B (0.67) GSK3BCES1CA1CA2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-103096892-B Pharmaceutical composition containing carbamoyloxy group arylalkanoyl arylpiperazine compound SK BIOPHARMACEUTICALS CO.,LTD. (KR) 2015-08-12 CN disclosed
US-6107479-A INTRODUCING A NONREMOVABLE LIPOPHILIC CAPPING GROUP TO AN UNREACTED REACTIVE GROUP OF OLIGOMER WHICH WAS NOT CHAIN EXTENDED IN PREVIOUS STEP, THEN SEPARATING CAPPED OLIGOMER FROM ELONGATED OLIGOMER ON A HYDROPHOBIC STATIONARY PHASE NOVARTIS AG (CH) 2000-08-22 US disclosed
WO-1998020018-A1 PROCESS FOR THE PREPARATION OF AN OLIGOMERIC COMPOUND NOVARTIS AG (CH) 1998-05-14 WO disclosed